Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SCMP > SEC Filings for SCMP > Form 8-K on 27-Nov-2012All Recent SEC Filings




Regulation FD Disclosure, Other Events

Item 7.01. Regulation FD Disclosure.

On November 27, 2012, Sucampo Pharmaceuticals, Inc. (the "Company") will make a corporate update presentation with an analyst at the corporate headquarters in Bethesda, MD. On November 28 and 29, 2012, the Company will make a corporate update presentation with one-on-one meetings with investors in New York, NY. Both meetings will include slides that have been previously disclosed.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

Under the direction of Sucampo AG ("SAG"), a wholly owned subsidiary of the Company, which holds the patents and intellectual property, Sucampo Pharma, Ltd. ("SPL"), a wholly owned subsidiary of the Company located in Japan, conducts clinical trials and seeks marketing approvals in that market for SAG's products and compounds. Under the terms of the February 19, 2009 agreement between SPL and Abbott Japan Co. Ltd. ("Abbott Japan") to develop and commercialize lubiprostone in Japan for the treatment of CIC, Abbott Japan will pay a development milestone of $15.0 million within 15 days of the first commercial sale of lubiprostone in Japan, which occurred on November 21, 2012. The payment will be made to SAG.

  Add SCMP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SCMP - All Recent SEC Filings
Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.